NV-HISENSE
5.1.2023 18:01:49 CET | Business Wire | Press release
The Hisense Group is pleased to announce that it has joined the Connectivity Standards Alliance and will bring support for the Matter protocol to its products starting in 2023, helping to simplify and elevate consumers’ experience through seamless integration and interoperability of all their smart home devices. Hisense Group's portfolio includes consumer electronics and home appliance brands such as Hisense, Toshiba, Gorenje, ASKO, and ATAG, as well as smart device platforms such as ConnectLife and VIDAA.
These brands will grow to include Matter compatible electronics and appliances going forward.
Matter is a new, open smart home protocol supported by many companies, both major leaders and smaller players, creating an unmatched force in the future of smart homes. Matter strives to ensure seamless connectivity of all devices, from a lightbulb to smart TVs to major domestic appliances, without worrying about compatibility.
“As the world’s #2 and China's #1 TV manufacturer and a top tier manufacturer for home appliances, Hisense is committed to enhancing consumers’ lives and experiences with the adoption of Matter,” said David Gold, President of Hisense USA. “Matter will enable consumers to enjoy all the core features and benefits that the Hisense Group’s products offer while integrating seamlessly with their preferred apps and smart devices to help streamline and maximize their smart home setup.”
“The adoption of Matter by our member Hisense is another example of a global consumer electronics company seeing the value that it brings to the IoT ecosystem, delivering a more secure, open standard that benefits consumers and manufacturers alike,” said Chris LaPre, Head of Technology, Connectivity Standards Alliance. “We’re excited to see how quickly the standard is becoming a must-have component to categories like televisions and appliances, and we value the global scale that Hisense brings to the table.”
Thanks to Matter, users will be able to use all their Matter enabled smart devices on the same platform. Once set up, it will be easy to connect all Matter devices with preferred apps and ecosystems and enable the use of basic applications - such as the simple operation of devices and integration into smart home systems. With that, upcoming generations of smart devices from the Hisense Group will be Matter compatible.
About Hisense
Hisense is headquartered in Qingdao, China. In the past 54 years, Hisense has always been adhering to the core values of "Integrity, Innovation, Customer Focus, and Sustainability" and the development strategy of "Sound Technological Foundation and Robust Operation". The business covers areas including multimedia, home appliances, IT intelligent information and modern service industries. With the rapid development in recent year, Hisense business is expended to more than 160 countries and regions. Smart TV which is the core of Hisense B2C business has always been at the forefront of the global industry. Besides B2C, Hisense is also in the global leading place in B2B industries including Intelligent Transportation, Precision Medicine and Optical Communications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005382/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom